14,102 Shares in Disc Medicine, Inc. (NASDAQ:IRON) Bought by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 14,102 shares of the company's stock, valued at approximately $636,000. Teachers Retirement System of The State of Kentucky owned about 0.06% of Disc Medicine at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Perceptive Advisors LLC raised its position in Disc Medicine by 14.2% during the 4th quarter. Perceptive Advisors LLC now owns 1,023,045 shares of the company's stock valued at $59,091,000 after purchasing an additional 127,404 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in shares of Disc Medicine by 19.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 785,000 shares of the company's stock worth $45,342,000 after acquiring an additional 130,000 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in shares of Disc Medicine in the 1st quarter worth approximately $7,429,000. Jennison Associates LLC raised its position in shares of Disc Medicine by 349.1% in the 1st quarter. Jennison Associates LLC now owns 193,240 shares of the company's stock worth $12,031,000 after acquiring an additional 150,209 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Disc Medicine by 59.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company's stock worth $58,788,000 after acquiring an additional 353,382 shares in the last quarter. Institutional investors own 83.70% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IRON. Wells Fargo & Company began coverage on Disc Medicine in a research report on Thursday, August 22nd. They issued an "overweight" rating and a $75.00 target price for the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a research report on Friday, September 20th. HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of Disc Medicine in a research report on Monday, September 16th. BMO Capital Markets reaffirmed an "outperform" rating and set a $70.00 price objective (up previously from $50.00) on shares of Disc Medicine in a research report on Monday, June 17th. Finally, Wedbush reaffirmed an "outperform" rating and set a $57.00 price objective on shares of Disc Medicine in a research report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $64.13.

Disc Medicine Trading Down 0.4 %

IRON traded down $0.22 during trading on Friday, hitting $49.93. 177,733 shares of the company's stock traded hands, compared to its average volume of 350,796. The company's 50 day simple moving average is $47.67 and its two-hundred day simple moving average is $42.07. Disc Medicine, Inc. has a 12-month low of $25.60 and a 12-month high of $77.60. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -14.77 and a beta of 0.59.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.08. On average, equities analysts expect that Disc Medicine, Inc. will post -4.19 EPS for the current year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.